Dual Phase I Studies to Determine the Dose of Cediranib (AZD2171) or AZD6244 to Use With Conventional Rectal Chemoradiotherapy (DREAMtherapy)

NCT01160926 Phase 1 TERMINATED

To determine the maximum tolerated dose (MTD) of AZD6244 or AZD2171 when combined with pre-operative capecitabine and radiotherapy in patients with locally advanced rectal cancer.

Details

Lead sponsor	The Christie NHS Foundation Trust
Phase	Phase 1
Status	TERMINATED
Enrolment	31
Start date	2010-07
Completion	2016-11-04

Conditions

• Rectal Cancer

Interventions

• AZD6244
• Cediranib (AZD2171)

Primary outcomes

• To determine the MTD (maximum tolerated dose) of AZD6244 or AZD2171 when combined with pre-operative capecitabine and radiotherapy in patients with locally advanced rectal cancer. — At point of surgery (10-12 weeks post treatment)

Countries

United Kingdom